Abstract
Strateos, a developer of data management and robotic systems for drug discovery, has raised $56.1 million in a series B investment round led by DCVC and Lux Capital. The company operates small-molecule and biologic-drug labs in San Diego and Menlo Park, California, where customers can remotely conduct experiments. Strateos opened the San Diego lab last year in partnership with Eli Lilly and Company, an investor in the financing round. The company was founded in 2012 as Transcriptic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
